These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 6679491)

  • 1. Efficacy control of HB blood donor screening.
    Fiedler H
    Haematologia (Budap); 1983; 16(1-4):99-104. PubMed ID: 6679491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis B virus DNA-positive, hepatitis B surface antigen-negative blood donations intercepted by anti-hepatitis B core antigen testing: the Canadian Blood Services experience.
    O'Brien SF; Fearon MA; Yi QL; Fan W; Scalia V; Muntz IR; Vamvakas EC
    Transfusion; 2007 Oct; 47(10):1809-15. PubMed ID: 17880605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 'How frequent is posttranfusion hepatitis after the introduction of 3rd generation donor screening for hepatitis B? What is its probable nature?
    Vox Sang; 1977; 32(6):346-63. PubMed ID: 898833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hepatitis B--significance for transfusion medicine].
    Jilg W
    Infusionsther Transfusionsmed; 1994 Aug; 21 Suppl 1():20-6. PubMed ID: 8000250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program.
    Satake M; Taira R; Yugi H; Hino S; Kanemitsu K; Ikeda H; Tadokoro K
    Transfusion; 2007 Jul; 47(7):1197-205. PubMed ID: 17581154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A revised method for estimating hepatitis B virus transfusion residual risk based on antibody to hepatitis B core antigen incident cases.
    Laperche S; Maniez M; Barlet V; El Ghouzzi MH; Le Vacon F; Levayer T; Lunel F; Morel P; Mouillot L; Piquet Y; Pillonel J;
    Transfusion; 2008 Nov; 48(11):2308-14. PubMed ID: 18673347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective assessment of donor blood screening for antibody to hepatitis C virus and high-titer antibody to HBcAg as a means of preventing posttransfusion hepatitis.
    Takano S; Omata M; Ohto M; Satomura Y
    Hepatology; 1993 Aug; 18(2):235-9. PubMed ID: 8393422
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of posttransfusion hepatitis B and C by screening for antibody to hepatitis C virus and antibody to HBcAg.
    Chung HT; Lee JS; Lok AS
    Hepatology; 1993 Nov; 18(5):1045-9. PubMed ID: 7693569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A simple strategy to look back on posttransfusion hepatitis B in a multitransfused patient.
    Jongerius JM; van der Poel CL; van Leeuwen EF
    Vox Sang; 1998; 75(1):66-9. PubMed ID: 9745157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors?
    Busch MP
    Transfus Clin Biol; 2004 Feb; 11(1):26-32. PubMed ID: 14980546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of an algorithm for the reentry of volunteer blood donors deferred due to false-positive test results for antibody to hepatitis B core antigen.
    Katz L; Strong DM; Tegtmeier G; Stramer S
    Transfusion; 2008 Nov; 48(11):2315-22. PubMed ID: 18647367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Markers for transfusion-associated hepatitis in north Indian blood donors: prevalence and trends.
    Singh B; Verma M; Verma K
    Jpn J Infect Dis; 2004 Apr; 57(2):49-51. PubMed ID: 15118208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donor screening for hepatitis B virus infection in a cell and tissue bank.
    Solves P; Mirabet V; Alvarez M; Vila E; Quiles F; Villalba JV; Montoro JA; Soler MA; Roig RJ
    Transpl Infect Dis; 2008 Dec; 10(6):391-5. PubMed ID: 18665905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies for the prevention of post-transfusion hepatitis.
    Mintz PD
    Ann Clin Lab Sci; 1984; 14(3):198-207. PubMed ID: 6428295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy.
    Kuhns MC; Kleinman SH; McNamara AL; Rawal B; Glynn S; Busch MP;
    Transfusion; 2004 Sep; 44(9):1332-9. PubMed ID: 15318857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-hepatits B core antigen testing, viral markers, and occult hepatitis B virus infection in Pakistani blood donors: implications for transfusion practice.
    Bhatti FA; Ullah Z; Salamat N; Ayub M; Ghani E
    Transfusion; 2007 Jan; 47(1):74-9. PubMed ID: 17207233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occult hepatitis B virus infection: implications in transfusion.
    Allain JP
    Vox Sang; 2004 Feb; 86(2):83-91. PubMed ID: 15023176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Italian blood donors with anti-HBc and occult hepatitis B virus infection.
    Manzini P; Girotto M; Borsotti R; Giachino O; Guaschino R; Lanteri M; Testa D; Ghiazza P; Vacchini M; Danielle F; Pizzi A; Valpreda C; Castagno F; Curti F; Magistroni P; Abate ML; Smedile A; Rizzetto M
    Haematologica; 2007 Dec; 92(12):1664-70. PubMed ID: 18055990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should antibody to hepatitis B core antigen be tested in routine screening of donor corneas for transplant?
    Mattern RM; Cavanagh HD
    Cornea; 1997 Mar; 16(2):138-45. PubMed ID: 9071525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [HBV-DNA positive findings in HBsAg negative blood donors and patients].
    Hennig H; Dennin RH; Haase D; Kirchner H
    Beitr Infusionsther Transfusionsmed; 1997; 34():26-30. PubMed ID: 9417346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.